Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

817
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
817
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

393
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
393
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

460
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

212
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uncovering the genetic basis of crown rust resistance in a northern-by-southern oat biparental population.

PloS one·2026
Same author

Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation System.

Gastro hep advances·2026
Same author

Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.

Hepatology (Baltimore, Md.)·2026
Same author

The Effect of an Exertion Protocol on Cognitive and Functional Performance in Adolescents After Concussion.

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine·2026
Same author

Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial.

Journal of hepatology·2026
Same author

Sex-based differences in pediatric lateral ankle avulsion fractures: males are more likely to sustain avulsion fractures.

The Physician and sportsmedicine·2026

Related Experiment Video

Updated: Feb 19, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.7K

Pharmacotherapy for NASH: Current and emerging.

Monica A Konerman1, Jacob C Jones2, Stephen A Harrison3

  • 1University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI, USA.

Journal of Hepatology
|November 11, 2017
PubMed
Summary

Non-alcoholic fatty liver disease (NAFLD), particularly its progressive form non-alcoholic steatohepatitis (NASH), lacks approved drug treatments despite its global prevalence. Ongoing research explores various targets to address this critical unmet medical need.

Keywords:
Clinical trialsFibrosisHepatitisNon-alcoholic steatohepatitisSteatosis

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.0K

Related Experiment Videos

Last Updated: Feb 19, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.7K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.0K

Area of Science:

  • Hepatology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Non-alcoholic fatty liver disease (NAFLD) is a widespread chronic liver condition linked to obesity.
  • Non-alcoholic steatohepatitis (NASH), a progressive form of NAFLD, elevates the risk of severe health issues and death.
  • Currently, no pharmacologic therapies are approved for NASH, highlighting a significant unmet medical need.

Purpose of the Study:

  • To review the current landscape of pharmacologic treatments under investigation for NASH.
  • To discuss the challenges and progress in developing effective therapies for NASH.
  • To examine the potential of investigational drugs targeting metabolic, inflammatory, and fibrotic pathways.

Main Methods:

  • Review of current drug development strategies for NASH.
  • Analysis of therapeutic targets including metabolic pathways, inflammation, and fibrosis.
  • Evaluation of clinical trial outcomes for compounds in various developmental stages.

Main Results:

  • Phase IIa compounds show promise for improving NASH histopathology.
  • Later-stage drug candidates demonstrate modest effects on steatosis, necroinflammation, and fibrosis.
  • Challenges in clinical trial design and enrollment persist.

Conclusions:

  • Despite modest results, investigational NASH therapies offer potential benefits.
  • Further research focusing on long-term safety and efficacy in diverse populations is crucial.
  • Approved pharmacologic treatments are needed to reduce morbidity and mortality in NASH patients.